RICHMOND, Va. / May 28, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer, will participate in a webcasted fireside chat at 11:00 a.m. Eastern Daylight Time on Wednesday, May 29, 2024 at Leerink Partners’ Healthcare Crossroads Conference in Austin, Texas. Owens & Minor is also hosting one-on-one meetings with investors at the conference.
Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations at least 10 minutes in advance to register for the live webcast of the discussion.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
Last Trade: | US$4.72 |
Daily Change: | -0.04 -0.84 |
Daily Volume: | 3,484,493 |
Market Cap: | US$364.570M |
October 07, 2025 September 15, 2025 August 11, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load